$RPRX
Royalty Pharma plc

2021 Q2 Form 10-Q Financial Statement

#000180276821000026 Filed on August 11, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2
Revenue $555.0M $510.9M
YoY Change 8.62% 11.65%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $44.92M $42.80M
YoY Change 4.96% 41.25%
% of Gross Profit
Research & Development $3.100M $5.776M
YoY Change -46.33% -73.13%
% of Gross Profit
Depreciation & Amortization $5.733M $5.700M
YoY Change 0.58% 0.0%
% of Gross Profit
Operating Expenses $3.100M $5.776M
YoY Change -46.33% -73.13%
Operating Profit $744.9M $409.3M
YoY Change 81.99% 24.85%
Interest Expense $37.43M $34.19M
YoY Change 9.47% -50.57%
% of Operating Profit 5.02% 8.35%
Other Income/Expense, Net $61.81M $192.6M
YoY Change -67.91% -229.2%
Pretax Income $806.8M $602.0M
YoY Change 34.02% 236.73%
Income Tax $0.00 $0.00
% Of Pretax Income 0.0% 0.0%
Net Earnings $440.8M $442.1M
YoY Change -0.29% 191.39%
Net Earnings / Revenue 79.42% 86.52%
Basic Earnings Per Share $1.08 $0.09
Diluted Earnings Per Share $1.08 $0.09
COMMON SHARES
Basic Shares Outstanding 409.3M shares 354.0M shares
Diluted Shares Outstanding 607.2M shares 354.0M shares

Balance Sheet

Concept 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.211B $2.472B
YoY Change -51.01%
Cash & Equivalents $1.142B $2.443B
Short-Term Investments $68.70M $28.50M
Other Short-Term Assets $12.10M $12.79M
YoY Change -5.4%
Inventory
Prepaid Expenses
Receivables $34.14M $32.00M
Other Receivables $10.69M $3.000M
Total Short-Term Assets $2.707B $3.391B
YoY Change -20.15%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $465.6M $430.3M
YoY Change 8.21%
Other Assets $5.960M $0.00
YoY Change
Total Long-Term Assets $13.81B $12.29B
YoY Change 12.3%
TOTAL ASSETS
Total Short-Term Assets $2.707B $3.391B
Total Long-Term Assets $13.81B $12.29B
Total Assets $16.51B $15.69B
YoY Change 5.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.393M $34.00M
YoY Change -72.37%
Accrued Expenses $152.9M $112.0M
YoY Change 36.52%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $182.2M
YoY Change -100.0%
Total Short-Term Liabilities $284.0M $451.0M
YoY Change -37.03%
LONG-TERM LIABILITIES
Long-Term Debt $5.826B $5.730B
YoY Change 1.67%
Other Long-Term Liabilities $110.0M
YoY Change
Total Long-Term Liabilities $5.826B $5.840B
YoY Change -0.24%
TOTAL LIABILITIES
Total Short-Term Liabilities $284.0M $451.0M
Total Long-Term Liabilities $5.826B $5.840B
Total Liabilities $6.110B $6.291B
YoY Change -2.88%
SHAREHOLDERS EQUITY
Retained Earnings $2.292B $1.571B
YoY Change 45.86%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $2.662M $2.119M
YoY Change 25.63%
Treasury Stock Shares
Shareholders Equity $5.734B $4.157B
YoY Change
Total Liabilities & Shareholders Equity $16.51B $15.69B
YoY Change 5.29%

Cashflow Statement

Concept 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income $440.8M $442.1M
YoY Change -0.29% 191.39%
Depreciation, Depletion And Amortization $5.733M $5.700M
YoY Change 0.58% 0.0%
Cash From Operating Activities $531.7M $489.0M
YoY Change 8.74% 45.15%
INVESTING ACTIVITIES
Capital Expenditures -$180.6M -$475.3M
YoY Change -61.99% 1931.2%
Acquisitions
YoY Change
Other Investing Activities $306.8M $226.0M
YoY Change 35.76% -267.53%
Cash From Investing Activities $126.2M -$249.4M
YoY Change -150.59% 57.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -224.4M 1.580B
YoY Change -114.21% -609.35%
NET CHANGE
Cash From Operating Activities 531.7M 489.0M
Cash From Investing Activities 126.2M -249.4M
Cash From Financing Activities -224.4M 1.580B
Net Change In Cash 433.5M 1.819B
YoY Change -76.17% -1483.35%
FREE CASH FLOW
Cash From Operating Activities $531.7M $489.0M
Capital Expenditures -$180.6M -$475.3M
Free Cash Flow $712.4M $964.3M
YoY Change -26.13% 167.64%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001802768
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
9997000 USD
CY2019 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201613Member
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39329
dei Entity Registrant Name
EntityRegistrantName
Royalty Pharma plc
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
X0
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1535773
dei Entity Address Address Line1
EntityAddressAddressLine1
110 East 59th Street
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10022
dei City Area Code
CityAreaCode
212
dei Local Phone Number
LocalPhoneNumber
883-0200
dei Security12b Title
Security12bTitle
Class A ordinary shares, par value $0.0001
dei Trading Symbol
TradingSymbol
RPRX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1142281000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1008680000 USD
CY2021Q2 us-gaap Trading Securities Debt
TradingSecuritiesDebt
842685000 USD
CY2020Q4 us-gaap Trading Securities Debt
TradingSecuritiesDebt
983279000 USD
CY2021Q2 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
596851000 USD
CY2020Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
587193000 USD
CY2021Q2 rprx Accrued Royalty Receivable
AccruedRoyaltyReceivable
34143000 USD
CY2020Q4 rprx Accrued Royalty Receivable
AccruedRoyaltyReceivable
33155000 USD
CY2021Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
68702000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
69984000 USD
CY2021Q2 rprx Other Royalty Income Receivable Current
OtherRoyaltyIncomeReceivableCurrent
10694000 USD
CY2020Q4 rprx Other Royalty Income Receivable Current
OtherRoyaltyIncomeReceivableCurrent
6011000 USD
CY2021Q2 us-gaap Other Assets Current
OtherAssetsCurrent
12098000 USD
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
8596000 USD
CY2021Q2 us-gaap Assets Current
AssetsCurrent
2707454000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
2696898000 USD
CY2021Q2 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
12932077000 USD
CY2020Q4 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
12368084000 USD
CY2021Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
17262000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
28666000 USD
CY2021Q2 us-gaap Equity Securities Fvni Noncurrent
EquitySecuritiesFVNINoncurrent
184042000 USD
CY2020Q4 us-gaap Equity Securities Fvni Noncurrent
EquitySecuritiesFVNINoncurrent
298689000 USD
CY2021Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
202498000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
163016000 USD
CY2021Q2 us-gaap Equity Method Investments
EquityMethodInvestments
465620000 USD
CY2020Q4 us-gaap Equity Method Investments
EquityMethodInvestments
454936000 USD
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5960000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
6124471000 USD
CY2021Q2 us-gaap Assets
Assets
16514913000 USD
CY2020Q4 us-gaap Assets
Assets
16020286000 USD
CY2021Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
117378000 USD
CY2020Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
126366000 USD
CY2021Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
9393000 USD
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
10775000 USD
CY2021Q2 us-gaap Interest Payable Current
InterestPayableCurrent
42904000 USD
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
42146000 USD
CY2021Q2 rprx Accrued Purchase Obligation Current
AccruedPurchaseObligationCurrent
110000000 USD
CY2020Q4 rprx Accrued Purchase Obligation Current
AccruedPurchaseObligationCurrent
110000000 USD
CY2021Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4314000 USD
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
18600000 USD
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
283989000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
307887000 USD
CY2021Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5825559000 USD
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5816584000 USD
CY2021Q2 us-gaap Liabilities
Liabilities
6109548000 USD
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q2 rprx Deferred Shares Par Or Stated Value Per Share
DeferredSharesParOrStatedValuePerShare
0.000001
CY2020Q4 rprx Deferred Shares Par Or Stated Value Per Share
DeferredSharesParOrStatedValuePerShare
0.000001
CY2021Q2 rprx Deferred Shares Shares Outstanding
DeferredSharesSharesOutstanding
355217000 shares
CY2021Q2 rprx Deferred Shares Shares Issued
DeferredSharesSharesIssued
355217000 shares
CY2020Q4 rprx Deferred Shares Shares Issued
DeferredSharesSharesIssued
316407000 shares
CY2020Q4 rprx Deferred Shares Shares Outstanding
DeferredSharesSharesOutstanding
316407000 shares
CY2021Q2 rprx Deferred Shares Value Issued
DeferredSharesValueIssued
0 USD
CY2020Q4 rprx Deferred Shares Value Issued
DeferredSharesValueIssued
0 USD
CY2021Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3415598000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2865964000 USD
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2291966000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1920635000 USD
CY2021Q2 us-gaap Minority Interest
MinorityInterest
4671686000 USD
CY2020Q4 us-gaap Minority Interest
MinorityInterest
5077036000 USD
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
28672000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
34395000 USD
CY2021Q2 us-gaap Treasury Stock Value
TreasuryStockValue
2662000 USD
CY2020Q4 us-gaap Treasury Stock Value
TreasuryStockValue
2317000 USD
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
10405365000 USD
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9895815000 USD
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16514913000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16020286000 USD
CY2021Q2 us-gaap Revenues
Revenues
554963000 USD
CY2020Q2 us-gaap Revenues
Revenues
510932000 USD
us-gaap Revenues
Revenues
1127990000 USD
us-gaap Revenues
Revenues
1011811000 USD
CY2021Q2 us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
-243762000 USD
CY2020Q2 us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
47278000 USD
us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
48499000 USD
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-32798000 USD
CY2021Q2 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
55495000 USD
us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
135290000 USD
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3122000 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5776000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5763000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13415000 USD
CY2021Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5733000 USD
CY2020Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5733000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
11404000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
11466000 USD
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
44921000 USD
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
42799000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
88077000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
80864000 USD
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
-189986000 USD
CY2020Q2 us-gaap Costs And Expenses
CostsAndExpenses
101586000 USD
us-gaap Costs And Expenses
CostsAndExpenses
153743000 USD
us-gaap Costs And Expenses
CostsAndExpenses
241035000 USD
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
744949000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
409346000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
974247000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
770776000 USD
CY2021Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
17701000 USD
CY2020Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
29292000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
15783000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
20218000 USD
CY2021Q2 us-gaap Interest Expense
InterestExpense
37426000 USD
CY2020Q2 us-gaap Interest Expense
InterestExpense
34189000 USD
us-gaap Interest Expense
InterestExpense
74841000 USD
us-gaap Interest Expense
InterestExpense
87773000 USD
CY2021Q2 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-1909000 USD
CY2020Q2 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
647000 USD
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-4464000 USD
CY2020Q2 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
193895000 USD
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
1309000 USD
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
40729000 USD
CY2021Q2 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
14015000 USD
CY2020Q2 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
0 USD
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
23130000 USD
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
0 USD
CY2021Q2 us-gaap Investment Income Net
InvestmentIncomeNet
14037000 USD
CY2020Q2 us-gaap Investment Income Net
InvestmentIncomeNet
2724000 USD
us-gaap Investment Income Net
InvestmentIncomeNet
30635000 USD
us-gaap Investment Income Net
InvestmentIncomeNet
5582000 USD
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-107000 USD
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
261000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-65000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5662000 USD
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
61806000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-59704000 USD
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
806755000 USD
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
192630000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8513000 USD
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
601976000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
965734000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
711072000 USD
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2021Q2 us-gaap Profit Loss
ProfitLoss
806755000 USD
CY2020Q2 us-gaap Profit Loss
ProfitLoss
601976000 USD
us-gaap Profit Loss
ProfitLoss
965734000 USD
us-gaap Profit Loss
ProfitLoss
711072000 USD
CY2021Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
365979000 USD
CY2020Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
159902000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
455839000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
197758000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
440776000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
442074000 USD
us-gaap Net Income Loss
NetIncomeLoss
509895000 USD
us-gaap Net Income Loss
NetIncomeLoss
513314000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax
0 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax
0 USD
us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax
0 USD
us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax
4066000 USD
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
6025000 USD
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
6949000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
11150000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
59674000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
13299000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
0 USD
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
28790000 USD
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
0 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-7274000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
6949000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-17640000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
63740000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
3231000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
-1624000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
8112000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
-11296000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-4043000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
5325000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-9528000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
52444000 USD
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
436733000 USD
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.08
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.09
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
447399000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
500367000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
565758000 USD
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.28
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.09
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.08
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.09
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
409344000 shares
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
353979000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
399606000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
353979000 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
607163000 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
353980000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
607151000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
353980000 shares
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9837033000 USD
CY2021Q2 rprx Noncontrolling Interest Increase From Contributions
NoncontrollingInterestIncreaseFromContributions
11519000 USD
CY2021Q2 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
170808000 USD
CY2021Q2 us-gaap Dividends Cash
DividendsCash
72581000 USD
CY2021Q2 us-gaap Stockholders Equity Other
StockholdersEquityOther
0 USD
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
721000 USD
CY2021Q2 us-gaap Profit Loss
ProfitLoss
806755000 USD
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
6025000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
13299000 USD
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
10405365000 USD
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
7162693000 USD
CY2020Q2 rprx Noncontrolling Interest Increase From Contributions
NoncontrollingInterestIncreaseFromContributions
6691000 USD
CY2020Q2 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
296483000 USD
CY2020Q2 rprx Stock Issued During Period Value Issued For Registration
StockIssuedDuringPeriodValueIssuedForRegistration
63000 USD
CY2020Q2 us-gaap Profit Loss
ProfitLoss
515789000 USD
CY2020Q2 rprx Stock Issued During Period Value Issued To Partnerships
StockIssuedDuringPeriodValueIssuedToPartnerships
1000 USD
CY2020Q2 rprx Stockholders Equity Value Effect Of Exchange And Reallocation
StockholdersEquityValueEffectOfExchangeAndReallocation
-1000 USD
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1909332000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3740000 USD
CY2020Q2 us-gaap Profit Loss
ProfitLoss
86187000 USD
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
6949000 USD
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9394961000 USD
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9895815000 USD
rprx Noncontrolling Interest Increase From Contributions
NoncontrollingInterestIncreaseFromContributions
14772000 USD
us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
316186000 USD
us-gaap Dividends Cash
DividendsCash
138564000 USD
us-gaap Stockholders Equity Other
StockholdersEquityOther
0 USD
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1434000 USD
us-gaap Profit Loss
ProfitLoss
965734000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
11150000 USD
rprx Noncontrolling Interest Increase From Contributions
NoncontrollingInterestIncreaseFromContributions
1447965000 USD
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
28790000 USD
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
10405365000 USD
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6141438000 USD
rprx Noncontrolling Interest Transfers Of Interests
NoncontrollingInterestTransfersOfInterests
0 USD
us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
689684000 USD
rprx Stock Issued During Period Value Issued For Registration
StockIssuedDuringPeriodValueIssuedForRegistration
63000 USD
us-gaap Profit Loss
ProfitLoss
624885000 USD
rprx Stock Issued During Period Value Issued To Partnerships
StockIssuedDuringPeriodValueIssuedToPartnerships
1000 USD
rprx Stockholders Equity Value Effect Of Exchange And Reallocation
StockholdersEquityValueEffectOfExchangeAndReallocation
-1000 USD
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1909332000 USD
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3740000 USD
CY2020Q2 us-gaap Profit Loss
ProfitLoss
86187000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
59674000 USD
us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax
4066000 USD
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9394961000 USD
rprx Proceeds From Cash Collections From Royalties Received On Financing Receivables
ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables
1094094000 USD
rprx Proceeds From Cash Collections From Royalties Received On Financing Receivables
ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables
1003504000 USD
rprx Proceeds From Cash Collections From Royalties Received On Intangible Assets
ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets
75200000 USD
rprx Proceeds From Cash Collections From Royalties Received On Intangible Assets
ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets
69646000 USD
rprx Proceeds From Cash Collections From Other Royalties Received On Financing Receivables
ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables
14088000 USD
rprx Proceeds From Cash Collections From Other Royalties Received On Financing Receivables
ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables
8548000 USD
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
22003000 USD
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
31840000 USD
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
2332000 USD
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
3597000 USD
rprx Proceeds From Collateral Received On Derivative Instruments
ProceedsFromCollateralReceivedOnDerivativeInstruments
11470000 USD
rprx Proceeds From Collateral Received On Derivative Instruments
ProceedsFromCollateralReceivedOnDerivativeInstruments
45252000 USD
rprx Payments For Collateral Posted On Derivative Instruments
PaymentsForCollateralPostedOnDerivativeInstruments
9340000 USD
rprx Payments For Collateral Posted On Derivative Instruments
PaymentsForCollateralPostedOnDerivativeInstruments
0 USD
rprx Payments To Terminate Derivative Instruments
PaymentsToTerminateDerivativeInstruments
0 USD
rprx Payments To Terminate Derivative Instruments
PaymentsToTerminateDerivativeInstruments
35448000 USD
rprx Payments For Ongoing Development Stage Funding
PaymentsForOngoingDevelopmentStageFunding
5763000 USD
rprx Payments For Ongoing Development Stage Funding
PaymentsForOngoingDevelopmentStageFunding
13415000 USD
us-gaap Interest Paid Net
InterestPaidNet
83431000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1057820000 USD
rprx Payments For Operating Costs And Professional Services
PaymentsForOperatingCostsAndProfessionalServices
81764000 USD
rprx Payments For Operating Costs And Professional Services
PaymentsForOperatingCostsAndProfessionalServices
69985000 USD
us-gaap Interest Paid Net
InterestPaidNet
64500000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
960108000 USD
us-gaap Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
523000 USD
us-gaap Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
15084000 USD
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
17427000 USD
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
29262000 USD
rprx Payments To Acquire Equity Securities Fnni
PaymentsToAcquireEquitySecuritiesFNNI
0 USD
rprx Payments To Acquire Equity Securities Fnni
PaymentsToAcquireEquitySecuritiesFNNI
50000000 USD
rprx Proceeds From Issuance Of Equity Securities Fnni
ProceedsFromIssuanceOfEquitySecuritiesFNNI
109367000 USD
rprx Proceeds From Issuance Of Equity Securities Fnni
ProceedsFromIssuanceOfEquitySecuritiesFNNI
0 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
35170000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
0 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
31250000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
728025000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
703934000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
868689000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
336012000 USD
us-gaap Payments To Acquire Finance Receivables
PaymentsToAcquireFinanceReceivables
683741000 USD
us-gaap Payments To Acquire Finance Receivables
PaymentsToAcquireFinanceReceivables
574620000 USD
rprx Payments For Milestones
PaymentsForMilestones
18600000 USD
rprx Payments For Milestones
PaymentsForMilestones
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-473134000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1006720000 USD
rprx Payments For Distributions To Shareholders And Unitholders
PaymentsForDistributionsToShareholdersAndUnitholders
0 USD
rprx Payments For Distributions To Shareholders And Unitholders
PaymentsForDistributionsToShareholdersAndUnitholders
285355000 USD
us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
238197000 USD
us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
284546000 USD
rprx Payments To Noncontrolling Interests Other
PaymentsToNoncontrollingInterestsOther
86978000 USD
rprx Payments To Noncontrolling Interests Other
PaymentsToNoncontrollingInterestsOther
28055000 USD
rprx Proceeds From Noncontrolling Interests Research And Development
ProceedsFromNoncontrollingInterestsResearchAndDevelopment
5114000 USD
rprx Payment Of Dividends To Shareholders
PaymentOfDividendsToShareholders
138564000 USD
rprx Payment Of Dividends To Shareholders
PaymentOfDividendsToShareholders
0 USD
rprx Proceeds From Noncontrolling Interests Research And Development
ProceedsFromNoncontrollingInterestsResearchAndDevelopment
4080000 USD
rprx Proceeds From Noncontrolling Interests Other
ProceedsFromNoncontrollingInterestsOther
8574000 USD
rprx Proceeds From Noncontrolling Interests Other
ProceedsFromNoncontrollingInterestsOther
29984000 USD
rprx Repayments Of Long Term Debt Scheduled Payments
RepaymentsOfLongTermDebtScheduledPayments
0 USD
rprx Repayments Of Long Term Debt Scheduled Payments
RepaymentsOfLongTermDebtScheduledPayments
94200000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
5170396000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
6040000000 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
8819000 USD
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0 USD
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
1918229000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-451085000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2121956000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
133601000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2075344000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1008680000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
246199000 USD
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1142281000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2321543000 USD
us-gaap Use Of Estimates
UseOfEstimates
The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates. The results for the interim periods are not necessarily indicative of results for the full year. The precise extent to which the COVID-19 pandemic will impact our operational and financial performance will depend on various factors. To date, the pandemic has not materially impacted our financial performance and we do not believe it is reasonably likely to in the future. Due to the nature of our business, the effect of the COVID-19 pandemic may not be fully reflected in certain of our results of operations until future periods.
CY2020Q3 rprx Number Of Noncontrolling Interests Created
NumberOfNoncontrollingInterestsCreated
2 partnership
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adjustment to prior period presentation </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the preparation of our condensed consolidated interim financial statements for the three months ended September 30, 2020, we identified an adjustment to the classification of our short-term investments on our consolidated balance sheet, as of December 31, 2019 based on the original maturity dates of the investments. The adjustments resulted in an increase of $66.7 million and a decrease of $17.7 million in cash activity related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchases of marketable securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceeds from sales and maturities of marketable securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash used in investing activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the six months ended June 30, 2020, with a net impact on net cash flow from investing of $84.4 million. We evaluated the adjustment and determined that, based on our quantitative and qualitative analysis, it was not material to the condensed consolidated financial statements as of and for the six months ended June 30, 2020.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform to the current period presentation.</span></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, financial royalty assets and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances as of June 30, 2021 and December 31, 2020 were held with State Street and Bank of America. Our primary operating accounts significantly exceed the Federal Deposit Insurance Corporation limits.The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, AbbVie, Amgen, Bristol-Myers Squibb, Gilead, Johnson &amp; Johnson, Lilly, Merck, Pfizer, Novartis, Biogen, Roche/Genentech and Vertex.
CY2021Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
178381000 USD
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
92819000 USD
CY2021Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
271200000 USD
CY2021Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
68702000 USD
us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.17
CY2021Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
202498000 USD
CY2021Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
271200000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
145647000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
87353000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
233000000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
69984000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
163016000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
233000000 USD
CY2021Q2 us-gaap Derivative Notional Amount
DerivativeNotionalAmount
600000000.0 USD
rprx Payments To Terminate Derivative Instruments
PaymentsToTerminateDerivativeInstruments
35400000 USD
rprx Proceeds From Collateral Received On Derivative Instruments
ProceedsFromCollateralReceivedOnDerivativeInstruments
45300000 USD
CY2021Q2 us-gaap Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss
FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss
-28300000 USD
us-gaap Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss
FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss
10700000 USD
CY2020Q2 us-gaap Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss
FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss
-48500000 USD
us-gaap Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss
FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss
57500000 USD
CY2021Q2 us-gaap Notes Receivable Gross
NotesReceivableGross
14819532000 USD
CY2021Q2 rprx Financing Receivable Allowance For Credit Loss Changes In Expected Cash Flows
FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
931654000 USD
CY2021Q2 rprx Financing Receivables After Allowance For Credit Loss Changes In Expected Cash Flows
FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
13887878000 USD
CY2021Q2 rprx Financing Receivable Allowance For Credit Loss Cumulative Adjustment And Credit Loss Expense Reversal
FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal
358950000 USD
CY2021Q2 us-gaap Notes Receivable Net
NotesReceivableNet
13528928000 USD
CY2020Q4 us-gaap Notes Receivable Gross
NotesReceivableGross
14219101000 USD
CY2020Q4 rprx Financing Receivable Allowance For Credit Loss Changes In Expected Cash Flows
FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
940107000 USD
CY2020Q4 rprx Financing Receivables After Allowance For Credit Loss Changes In Expected Cash Flows
FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
13278994000 USD
CY2020Q4 rprx Financing Receivable Allowance For Credit Loss Cumulative Adjustment And Credit Loss Expense Reversal
FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal
323717000 USD
CY2020Q4 us-gaap Notes Receivable Net
NotesReceivableNet
12955277000 USD
CY2020Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
1263824000 USD
rprx Financing Receivable Change In Present Value Increases To Cumulative Allowance Expense
FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense
409793000 USD
rprx Financing Receivable Change In Present Value Decreases To Cumulative Allowance Reversal Of Expense
FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense
396526000 USD
us-gaap Financing Receivable Change In Present Value Expense Reversal
FinancingReceivableChangeInPresentValueExpenseReversal
-21719000 USD
us-gaap Provision For Loan Losses Expensed
ProvisionForLoanLossesExpensed
35232000 USD
CY2021Q2 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
1290604000 USD
CY2020Q4 rprx Financing Receivable Allowance For Credit Loss Cumulative Adjustment And Credit Loss Expense Reversal
FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal
323700000 USD
CY2021Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
606216000 USD
CY2021Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
588954000 USD
CY2021Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
17262000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
606216000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
577550000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
28666000 USD
CY2021Q2 rprx Research And Development Remaining Funding Commitment
ResearchAndDevelopmentRemainingFundingCommitment
11400000 USD
CY2021Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
174441000 USD
CY2020Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
183416000 USD
CY2021Q2 us-gaap Long Term Debt
LongTermDebt
5825559000 USD
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
5816584000 USD
CY2021Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 USD
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 USD
CY2021Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5825559000 USD
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5816584000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
P1Y
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
900000 USD
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
138600000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1700000 USD
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3700000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3700000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0 USD
CY2021Q2 us-gaap Profit Loss
ProfitLoss
806755000 USD
us-gaap Profit Loss
ProfitLoss
965734000 USD
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
440776000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
509895000 USD
CY2021Q2 us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
212961000 USD
us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
251506000 USD
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
653737000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
761401000 USD
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
409344000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
399606000 shares
CY2021Q2 us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
197773000 shares
us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
207508000 shares
CY2021Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
46000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
37000 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
607163000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
607151000 shares
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.28
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.25
CY2020Q2 us-gaap Profit Loss
ProfitLoss
601976000 USD
us-gaap Profit Loss
ProfitLoss
711072000 USD
CY2020Q2 rprx Net Income Loss Attributable To Parent Prior To Offering
NetIncomeLossAttributableToParentPriorToOffering
408602000 USD
rprx Net Income Loss Attributable To Parent Prior To Offering
NetIncomeLossAttributableToParentPriorToOffering
479842000 USD
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
33472000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
33472000 USD
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
353979000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
353979000 shares
CY2020Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1000 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
353980000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
353980000 shares
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.09
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.09
us-gaap Profit Loss
ProfitLoss
965734000 USD
us-gaap Profit Loss
ProfitLoss
711072000 USD
rprx Increase Decrease In Financial Royalty Assets
IncreaseDecreaseInFinancialRoyaltyAssets
1033039000 USD
rprx Increase Decrease In Financial Royalty Assets
IncreaseDecreaseInFinancialRoyaltyAssets
937021000 USD
us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
48499000 USD
us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
135290000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
11404000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
11466000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
9583000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
4340000 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-4464000 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-32798000 USD
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
1309000 USD
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
40729000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
15783000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
20218000 USD
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
22003000 USD
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
31840000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-5405000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1434000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
3740000 USD
rprx Investment Income Net Reclassification Of Available For Sale Debt Securities Gain Loss
InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss
28790000 USD
rprx Investment Income Net Reclassification Of Available For Sale Debt Securities Gain Loss
InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss
0 USD
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
23130000 USD
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
0 USD
rprx Gain Loss On Derivative Financial Instruments
GainLossOnDerivativeFinancialInstruments
0 USD
rprx Gain Loss On Derivative Financial Instruments
GainLossOnDerivativeFinancialInstruments
34952000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-2049000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-3398000 USD
rprx Increase Decrease In Cash Collections On Financing Receivables
IncreaseDecreaseInCashCollectionsOnFinancingReceivables
1094094000 USD
rprx Increase Decrease In Cash Collections On Financing Receivables
IncreaseDecreaseInCashCollectionsOnFinancingReceivables
1003504000 USD
rprx Increase Decrease In Accrued Royalty Receivable
IncreaseDecreaseInAccruedRoyaltyReceivable
988000 USD
rprx Increase Decrease In Accrued Royalty Receivable
IncreaseDecreaseInAccruedRoyaltyReceivable
-1218000 USD
rprx Increase Decrease In Other Royalty Income Receivable
IncreaseDecreaseInOtherRoyaltyIncomeReceivable
4683000 USD
rprx Increase Decrease In Other Royalty Income Receivable
IncreaseDecreaseInOtherRoyaltyIncomeReceivable
-2094000 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-3703000 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
12634000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-45635000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-913000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
13862000 USD
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
758000 USD
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
0 USD
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
2730000 USD
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
0 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1057820000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
960108000 USD
us-gaap Transfer Of Investments
TransferOfInvestments
0 USD
us-gaap Transfer Of Investments
TransferOfInvestments
303679000 USD
rprx Settlements With Equity Method Investments
SettlementsWithEquityMethodInvestments
0 USD
rprx Settlements With Equity Method Investments
SettlementsWithEquityMethodInvestments
5700000 USD
rprx Accrued Purchase Obligation Equity Investment
AccruedPurchaseObligationEquityInvestment
0 USD
rprx Accrued Purchase Obligation Equity Investment
AccruedPurchaseObligationEquityInvestment
220000000 USD
rprx Repayments Of Long Term Debt Contributions From Noncontrolling Interest Noncash
RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash
0 USD
rprx Repayments Of Long Term Debt Contributions From Noncontrolling Interest Noncash
RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash
1103774000 USD
rprx Milestone Payment Accrued But Not Paid
MilestonePaymentAccruedButNotPaid
0 USD
rprx Milestone Payment Accrued But Not Paid
MilestonePaymentAccruedButNotPaid
1610000 USD
rprx Accrued Capitalized Offering Costs
AccruedCapitalizedOfferingCosts
0 USD
rprx Accrued Capitalized Offering Costs
AccruedCapitalizedOfferingCosts
8897000 USD
CY2021Q2 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
117378000 USD
CY2020Q4 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
126366000 USD

Files In Submission

Name View Source Status
0001802768-21-000026-index-headers.html Edgar Link pending
0001802768-21-000026-index.html Edgar Link pending
0001802768-21-000026.txt Edgar Link pending
0001802768-21-000026-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
rprx-20210630.htm Edgar Link pending
rprx-20210630.xsd Edgar Link pending
rprx-20210630ex311.htm Edgar Link pending
rprx-20210630ex312.htm Edgar Link pending
rprx-20210630ex32.htm Edgar Link pending
rprx-20210630_cal.xml Edgar Link unprocessable
rprx-20210630_def.xml Edgar Link unprocessable
rprx-20210630_htm.xml Edgar Link completed
rprx-20210630_lab.xml Edgar Link unprocessable
rprx-20210630_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending